Why Age Changes the Peptide Conversation
Several key biological parameters change significantly after 50: GH and IGF-1 levels decline (somatopause), NAD+ levels drop substantially, collagen synthesis slows, and recovery from tissue damage takes longer. These changes are precisely the targets of many longevity peptide protocols — which is why the over-50 population has the most to potentially gain from this category of therapy.
Priority Protocols for Over-50 Patients
Physicians working with patients over 50 typically prioritize GH optimization (Sermorelin or CJC-1295 + Ipamorelin) with IGF-1 monitoring, NAD+ support for cellular energy, and GHK-Cu for skin and collagen maintenance. BPC-157 and TB-500 become increasingly relevant as recovery time from musculoskeletal issues extends with age.
What the Physician Evaluation Should Include
For patients over 50, a thorough peptide evaluation should include complete hormone panel, IGF-1, comprehensive metabolic panel, thyroid function, and cardiovascular risk assessment. The presence of age-related conditions (cardiovascular disease, diabetes, cancer history) significantly affects which protocols are appropriate and requires experienced clinical judgment.
Starting Conservative
Physicians typically start peptide protocols more conservatively in older patients — lower doses, more frequent monitoring, longer assessment periods before escalation. The goal is optimizing biology, not pushing it harder than it can support.